Therapeutic Antibodies – News and Features

Patients with advanced endometrial cancer saw a significant reduction in disease growth with the combination immunotherapy and chemotherapy.

Researchers have discovered how healthy bacteria can escape the intestine, travel to lymph nodes and cancerous tumors elsewhere in the body, and boost the effectiveness of certain immunotherapy drugs.

The anti-CD3 antibody drug used to treat COVID-19 has been trialed to treat other diseases and has been shown to reduce brain inflammation in multiple sclerosis patients.

Starting the immunotherapy drug pembrolizumab before surgery, instead of waiting until after surgery, significantly improves the outlook for patients with high-risk melanoma.

New research has highlighted the role of a tumor's necrotic core in promoting metastasis, linking necrosis, circulating tumor cells and metastasis.

This article walks through some of the foundational developments in the field of glycobiology that have powered the progress made in 2022 and what these advancements signal for the future.

This article will review the latest applications of mass spectrometry-based techniques across the stages of biopharmaceutical development and testing.

An oncolytic virotherapy has shown promise for treating triple-negative breast cancer.

New research from the Centre of Cancer Immunology has shown that changing how tightly an antibody binds to a target could improve treatments for cancer.

To learn more about the Pioneer Antibody Discovery Platform and its potential impact on drug discovery and development, we spoke to Dr. John Cardone.